MicroRNA-153 Functions As a Tumor Suppressor by Targeting SET7 and ZEB2 in Ovarian Cancer Cells
Authors
Affiliations
The overall goal of the present study was to find and validate unidentified miRNAs that regulate epithelial-mesenchymal transition (EMT) and proliferation in ovarian cancer. Furthermore, we demonstrate that the high expression of miR-153 in human epithelial ovarian cancer (EOC) is associated with better survival. The mean expression level of miR-153 in ovarian cancer was significantly lower than in the adjacent carcinoma tissue. In the present study, we report that miR-153 are negative regulators of SET7 and ZEB2, miR-153 regulates SET7/ZEB2 expression and promotes SET7/ZEB2 mRNA degradation. Further, confirmed by reporter assays, SET7/ZEB2 are downstream targets of miR-153 directly bound to the 3' untranslated region (3'-UTR). Clone formation and wound-healing assay as well as Transwell assay proved that silencing of SET7 or ZEB2 partially abolished the enhancement of cell proliferation and invasion induced by downregulated miR-153. SET7 and ZEB2 are negatively correlated with miR-153 expression in human ovarian cancer and indicated a worse survival. Considering the role of SET7 and ZEB2 in EOC, it is important to clarify how the expression of SET7 and ZEB2 are regulated. Based on our results miR-153 inhibits proliferation and suppresses EMT and the invasive potential of ovarian cancer cells through downregulation of SET7 and ZEB2, supporting the pursuit of miR-153 as a potential target for ovarian cancer intervention.
Wang B, Cai R, Sun T, Yang Z, Zhang H Heliyon. 2024; 10(13):e34243.
PMID: 39091947 PMC: 11292528. DOI: 10.1016/j.heliyon.2024.e34243.
Talukdar P, Chatterji U Signal Transduct Target Ther. 2023; 8(1):427.
PMID: 37953273 PMC: 10641101. DOI: 10.1038/s41392-023-01651-w.
Li T, Guo D, Xu X, Liu P, Wang P, Zhu Y Oncol Lett. 2023; 26(1):278.
PMID: 37274464 PMC: 10236043. DOI: 10.3892/ol.2023.13864.
[Research Progress of Role and Mechanism of SETD7 in Tumor Occurrence and Progression].
Cao L, Wang M, Xu K Zhongguo Fei Ai Za Zhi. 2023; 26(1):38-45.
PMID: 36792079 PMC: 9987127. DOI: 10.3779/j.issn.1009-3419.2023.106.02.
Yousefnia S Front Oncol. 2022; 12:985897.
PMID: 36158686 PMC: 9500380. DOI: 10.3389/fonc.2022.985897.